Cargando…
Co-Application of C16 and Ang-1 Improves the Effects of Levodopa in Parkinson Disease Treatment
BACKGROUND: Levodopa is regarded as a standard medication in Parkinson disease (PD) treatment. However, long-term administration of levodopa leads to levodopa-induced dyskinesia (LID), which can markedly affect patient quality of life. Previous studies have shown that neuroinflammation in the brain...
Autores principales: | Fu, Xiao-Xiao, Wang, Jin, Cai, Hua-Ying, Jiang, Hong, Jiang, Jin-Zhan, Chen, Hao-Hao, Han, Shu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273834/ https://www.ncbi.nlm.nih.gov/pubmed/35836722 http://dx.doi.org/10.2147/JIR.S368291 |
Ejemplares similares
-
C16 Peptide and Ang-1 Improve Functional Disability and Pathological Changes in an Alzheimer’s Disease Model Associated with Vascular Dysfunction
por: Fu, Xiaoxiao, et al.
Publicado: (2022) -
Effect of Acute Levodopa Up-Titration on Blood Pressure in Patients With Early Stage Parkinson’s Disease: Results of a Levodopa Challenge Test
por: He, Xiaoqin, et al.
Publicado: (2022) -
Efficacy and safety of combination therapy with pramipexole and levodopa vs levodopa monotherapy in patients with Parkinson disease: A systematic review and meta-analysis
por: Wang, Yan, et al.
Publicado: (2021) -
Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease
por: Conti, Valeria, et al.
Publicado: (2022) -
Comparison of Endothelial Progenitor Cells in Parkinson's Disease Patients Treated with Levodopa and Levodopa/COMT Inhibitor
por: Lee, Phil Hyu, et al.
Publicado: (2011)